F
Flora Zagouri
Researcher at National and Kapodistrian University of Athens
Publications - 321
Citations - 5102
Flora Zagouri is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 32, co-authored 280 publications receiving 3530 citations. Previous affiliations of Flora Zagouri include Alexandra Hospital & Medical University of Vienna.
Papers
More filters
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Shanu Modi,William Jacot,Toshinari Yamashita,Joohyuk Sohn,Maria Vidal,Eriko Tokunaga,Junji Tsurutani,Naoto Ueno,Aleix Prat,Yee Soo Chae,Keun Seok Lee,Naoki Niikura,Yeon Hee Park,Bing Xue,Xiao-juan Wang,Miguel Gil-Gil,Wei Liu,Jean-Yves Pierga,Seock-Ah Im,Halle C. F. Moore,Hope S. Rugo,Rinat Yerushalmi,Flora Zagouri,Andrea Gombos,Sung-Bae Kim,Qiang Liu,Ting Luo,Cristina Saura,Peter Schmid,Tao Sun,Dhiraj Gambhire,Lotus Yung,Yibin Wang,Jasmeet Singh,Patrik Vitazka,Gerold Meinhardt,Nadia Harbeck,David Cameron +37 more
TL;DR: In this phase 3 trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.
Journal ArticleDOI
Trastuzumab administration during pregnancy: a systematic review and meta-analysis
Flora Zagouri,Theodoros N. Sergentanis,Dimosthenis Chrysikos,Christos Papadimitriou,Meletios-Athanassios Dimopoulos,Rupert Bartsch +5 more
TL;DR: The present systematic review and meta-analysis aims to synthesize all available data, so as to evaluate the safety of trastuzumab during pregnancy, and found that all children exposed to trastzumab in utero exclusively in the first trimester were completely healthy at birth.
Journal ArticleDOI
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement
Hatem A. Azim,Stefan Michiels,Flora Zagouri,Suzette Delaloge,Martin Filipits,Moïse Namer,Patrick Neven,William Fraser Symmans,Alistair Thompson,Fabrice Andre,Sherene Loi,Charles Swanton +11 more
TL;DR: There is a need to develop models that integrate clinicopathologic factors along with genomic tests and demonstration of clinical utility should be made in the context of a prospective randomized trial and the creation of registries for patients who are subjected to genomic testing in the daily practice.
Journal ArticleDOI
Gynecologic cancers in pregnancy: Guidelines based on a third international consensus meeting
Frédéric Amant,Frédéric Amant,Paul Berveiller,Ingrid A. Boere,Elyce Cardonick,Robert Fruscio,Monica Fumagalli,Michael J. Halaska,Annette Hasenburg,A.L.V. Johansson,Matteo Lambertini,Christianne A.R. Lok,Charlotte Maggen,P. Morice,Fedro A. Peccatori,P. Poortmans,K. Van Calsteren,Tineke Vandenbroucke,M. van Gerwen,M.M. van den Heuvel-Eibrink,Flora Zagouri,Ignacio Zapardiel +21 more
TL;DR: Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health care providers and more studies aimed at the definition of the exact prognosis of patients after antenatal cancer treatment are warranted.
Journal ArticleDOI
Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis
Flora Zagouri,Theodoros N. Sergentanis,Rupert Bartsch,Anna S. Berghoff,Dimosthenis Chrysikos,Evandro de Azambuja,Meletios-Athanassios Dimopoulos,Matthias Preusser +7 more
TL;DR: IT trastuzumab administration seems to represent a safe and in some cases effective option for the treatment of HER2-positive breast cancer patients with leptomeningeal involvement, however, clinical trials are urgently needed to establish the definite role.